Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:02:36.955Z.
Calculation as of: 2026-10-06T18:02:36.955Z.
Quote observation: 2026-10-06T18:00:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a2c27257439ebc7e0324c407d6ec5b5d27bfaa5dcb56832ff3962ee146363265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$107.32M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.09M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.98M
Price/FCF Ratio
N/A
TTM Avg
23.61
3Y Avg
13.61
5Y Avg
10.78
Market Cap
$106.01M
Price/FCF Ratio
N/A
TTM Avg
8.08
3Y Avg
8.08
5Y Avg
8.08
Market Cap
$109.53M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$105.20M
Price/FCF Ratio
3.68
TTM Avg
4.64
3Y Avg
13.17
5Y Avg
35.61
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $107.47M | N/A | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.32M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | N/A | 23.61 | 13.61 | 10.78 |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $106.01M | N/A | 8.08 | 8.08 | 8.08 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.53M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.74M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | 3.68 | 4.64 | 13.17 | 35.61 |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.96M | N/A | 17.97 | 17.97 | 17.97 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
